The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
- Author:
Ju Young KIM
1
;
Chur Woo YOU
Author Information
- Publication Type:Original Article
- Keywords: Hemophilia A; Previously treated patient; Inhibitor; Risk factor
- MeSH: Diagnosis; Drug Therapy; Factor IX; Factor VIII; Hemophilia A; Hemorrhage; Humans; Isoantibodies; Korea; Prevalence; Risk Factors; Vaccination
- From:Blood Research 2019;54(3):204-209
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Risk factors for the development of inhibitors in previously untreated patients (PUPs) have been reported; this is not the case in previously treated patients (PTPs) owing to fewer studies. Risk factors may differ for the development of PTP versus PUP inhibitors. We aimed to identify risk factors for PTP inhibitor development. METHODS: Participants were patients at a hemophilia treatment center in Korea with current or past history of factor VIII or factor IX alloantibodies. Observed inhibitors were classified as PUP or PTP inhibitors based on the cumulative number of exposure days. We compared the type and severity of hemophilia, mutation type, and family history of inhibitor between PUPs and PTPs. Events within 3 months before the first inhibitor detection, such as change of the factor concentrate used, short-term high exposure or continuous infusion of factor concentrate, history of surgery, infection, diagnosis of cancer, use of immunosuppressive or immunomodulator agents, and vaccination were compared between PUPs and PTPs. RESULTS: We observed 5 PUP inhibitors and 5 PTP inhibitors in 115 patients with hemophilia A. Events that might be related to the development of inhibitors within 3 months prior to the first inhibitor detection were observed in all 5 PTPs. On the contrary, no such events were observed in any PUPs. The observed events included a change in the factor concentrate used, subsequent chemotherapy, and short-term high exposure to factor concentrates for controlling hemorrhage and surgeries. CONCLUSION: Our results suggest a greater role of nongenetic factors in PTP inhibitor development.
